Compugen to Present at Upcoming Antibody Industrial Symposium
Compugen (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, announced that its SVP of Preclinical Development and Corporate Operations, Pierre Ferré, Ph.D, will present at the 12th Antibody Industrial Symposium in Montpellier, France, on June 21, 2024. The presentation will focus on a case study regarding clinical dose selection for TIGIT monospecific and bispecific antibodies. This event is an important platform for discussing advancements in antibody research and development.
- Compugen's participation in a reputable event like the 12th Antibody Industrial Symposium enhances its visibility and credibility in the cancer immunotherapy field.
- Presentation on clinical dose selection for TIGIT antibodies, which are critical in cancer treatment, highlights Compugen’s innovative research and development efforts.
- The press release does not mention any new clinical data or financial updates, leaving investors without concrete information on recent progress or financial performance.
- Participation in symposiums, while good for visibility, does not directly translate to immediate financial gains or stock performance improvements.
HOLON,
Event: 12th Antibody Industrial Symposium, Montpellier,
Date: Friday, June 21, 2024
Presenter: Pierre Ferré, Ph.D., SVP, Preclinical Development and Corporate Operations, Compugen
Presentation title: Case study on clinical dose selection for TIGIT monospecific and bispecific antibodies
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, in IND enabling studies is licensed to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-present-at-upcoming-antibody-industrial-symposium-302174100.html
SOURCE Compugen Ltd.
FAQ
What event is Compugen presenting at?
What will Compugen present at the symposium?
Who from Compugen will present at the Antibody Industrial Symposium?
When is Compugen's presentation at the Antibody Industrial Symposium?
What is the focus of Compugen's presentation at the symposium?
